BIOS Fund II, LP — SEC insider filings
SEC reporting owner CIK 1714576. 34 insider filings on record with FilingPulse; latest filed 2026-10-30.
Transaction summary — filings shown
Covers all 34 filings on record, filed 2021-08-03 to 2026-10-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 42 legs across 12 filings — 6,482,095 shares, $13,351,588 total (shares × price as filed on priced legs).
- Open-market sales (code S, non-derivative): 71 legs across 12 filings — 1,611,847 shares, $4,111,512 total (shares × price as filed on priced legs).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 131.
- Largest priced transaction: purchase of 375,000 shares @ $8.00 ($3,000,000) in ACTUATE THERAPEUTICS, INC., filed 2024-08-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | Director, 10% owner | 5 | 3 legs · 571,428 sh · $4,499,996 | 6 legs · 49,998 sh · $424,983 | 65 |
| IN8BIO, INC. (INAB) | 10% owner | 10 | 24 legs · 2,026,113 sh · $3,909,627 | — | 24 |
| Lantern Pharma Inc. (LTRN) | 10% owner | 9 | — | 62 legs · 892,532 sh · $3,686,529 | 10 |
| Azitra Inc (AZTR) | 10% owner | 1 | 6 legs · 2,297,490 sh · $3,000,000 | 3 legs · 669,317 sh | 24 |
| COGNITION THERAPEUTICS INC (CGTX) | Director, 10% owner | 9 | 9 legs · 1,587,064 sh · $1,941,965 | — | 8 |
Insider filings — BIOS Fund II, LP
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-30 | 4 | ACTUATE THERAPEUTICS, INC. (ACTU) jointly with BIOS Fund I, LP, Bios 2024 Co-Invest, LP, BIOS Actuate Co-Invest I, LP, BIOS Actuate Co-Invest II, LP, Bios Actuate Co-Invest III, LP, Bios Clinical Opportunity Fund, LP, BIOS Fund I QP, LP, BIOS Fund II NT, LP, BIOS Fund II QP, LP | Grant/award (A): 64,995 (derivative) @ $0 · Grant/award (A): 87,743 (derivative) @ $0 · Grant/award (A): 682,885 (derivative) @ $0 · Grant/award (A): 194,984 (derivative) @ $0 · Grant/award (A): 368,304 (derivative) @ $0 · Grant/award (A): 47,972 (derivative) @ $0 · +7 more | EDGAR |
| 2026-06-22 | 4 | COGNITION THERAPEUTICS INC (CGTX) jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, BIOS Advisors GP, LLC, Bios Equity Partners, LP, BIOS Fund I, LP, BIOS Fund II QP, LP, BIOS Memory SPV I, LP, Bios Equity Partners II, LP, BIOS Fund I QP, LP | Grant/award (A): 25,000 @ $0 | EDGAR |
| 2025-06-30 | 4 | ACTUATE THERAPEUTICS, INC. (ACTU) jointly with Kreis Leslie W., Cavu Advisors, LLC, Cavu Management, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, Bios Equity Partners, LP, BIOS Fund II NT, LP, BIOS Fund II QP, LP, Bios Equity Partners II, LP | Purchase (P): 71,428 @ $7 · Purchase (P): 71,428 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | COGNITION THERAPEUTICS INC (CGTX) jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, BIOS Advisors GP, LLC, Bios Equity Partners, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Memory SPV I, LP, Bios Equity Partners II, LP, BIOS Fund II QP, LP | Grant/award (A): 34,000 @ $0 | EDGAR |
| 2025-06-13 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Sale (S): 3 @ $3.40 · Sale (S): 171 @ $3.40 · Sale (S): 10,925 @ $3.38 · Sale (S): 5 @ $3.40 · Sale (S): 293 @ $3.40 · Sale (S): 18,678 @ $3.38 · +9 more | EDGAR |
| 2025-06-13 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Sale (S): 7,206 @ $3.09 · Sale (S): 12,319 @ $3.09 · Sale (S): 1,903 @ $3.09 · Sale (S): 14,218 @ $3.09 · Sale (S): 4,354 @ $3.09 | EDGAR |
| 2025-05-29 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Sale (S): 3,790 @ $3.05 · Sale (S): 2,702 @ $2.87 · Sale (S): 3,639 @ $3.03 · Sale (S): 6,479 @ $3.05 · Sale (S): 4,620 @ $2.87 · Sale (S): 6,221 @ $3.03 · +9 more | EDGAR |
| 2025-05-07 | 4 | IN8BIO, INC. (INAB) jointly with Fletcher Aaron G.L., BIOS Fund II QP, LP, BIOS Fund II NT, LP, BIOS Incysus Co-Invest I, LP, Bios Clinical Opportunity Fund, LP, Bios Equity COF, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Purchase (P): 1,148,482 (derivative) · Other (J): 574,241 (derivative) · Other (J): 574,241 (derivative) | EDGAR |
| 2024-10-11 | 4 | IN8BIO, INC. (INAB) jointly with Fletcher Aaron G.L., BIOS Fund II QP, LP, BIOS Fund II NT, LP, BIOS Incysus Co-Invest I, LP, Bios Clinical Opportunity Fund, LP, Bios Equity COF, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Purchase (P): 709,040 (derivative) · Purchase (P): 709,040 (derivative) · Disposition to issuer (D): 574,241 (derivative) · Grant/award (A): 574,241 (derivative) | EDGAR |
| 2024-08-20 | 4/A | ACTUATE THERAPEUTICS, INC. (ACTU) jointly with Kreis Leslie W., Cavu Advisors, LLC, Cavu Management, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, Bios Equity Partners, LP, BIOS Fund II NT, LP, BIOS Fund II QP, LP, Bios Equity Partners II, LP | Sale (S): 5,314 @ $8 · Sale (S): 17,361 @ $8 · Sale (S): 2,324 @ $8 | EDGAR |
| 2024-08-14 | 4 | ACTUATE THERAPEUTICS, INC. (ACTU) jointly with Kreis Leslie W., Cavu Advisors, LLC, Cavu Management, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, Bios Equity Partners, LP, BIOS Fund II NT, LP, BIOS Fund II QP, LP, Bios Equity Partners II, LP | Conversion (C): 884,427 · Purchase (P): 375,000 @ $8 · Purchase (P): 125,000 @ $8 · Conversion (C): 525,797 · Conversion (C): 307,538 · Conversion (C): 141,457 · +50 more | EDGAR |
| 2024-08-14 | 4 | ACTUATE THERAPEUTICS, INC. (ACTU) jointly with Kreis Leslie W., Cavu Advisors, LLC, Cavu Management, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, Bios Equity Partners, LP, BIOS Fund II NT, LP, BIOS Fund II QP, LP, Bios Equity Partners II, LP | Holdings only — no transactions reported | EDGAR |
| 2024-06-11 | 4 | COGNITION THERAPEUTICS INC (CGTX) jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, BIOS Advisors GP, LLC, Bios Equity Partners, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Memory SPV I, LP, Bios Equity Partners II, LP, BIOS Fund II QP, LP | Grant/award (A): 8,500 @ $0 · Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Sale (S): 930 @ $6.25 · Sale (S): 1,859 @ $6.33 · Sale (S): 6,944 @ $6.25 · Sale (S): 13,888 @ $6.33 · Sale (S): 2,126 @ $6.25 · Sale (S): 4,253 @ $6.33 | EDGAR |
| 2024-02-29 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Sale (S): 4,649 @ $4.40 · Sale (S): 6,909 @ $4.85 · Sale (S): 1,832 @ $4.87 · Sale (S): 34,731 @ $4.40 · Sale (S): 51,608 @ $4.85 · Sale (S): 13,686 @ $4.87 · +3 more | EDGAR |
| 2024-01-19 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Option exercise/expiry (X): 7,347 @ $3.13 · Sale (S): 5,475 @ $4.20 · Option exercise/expiry (X): 54,873 @ $3.13 · Sale (S): 40,893 @ $4.20 · Option exercise/expiry (X): 16,801 @ $3.13 · Sale (S): 12,521 @ $4.20 · +3 more | EDGAR |
| 2023-12-14 | 4 | IN8BIO, INC. jointly with Fletcher Aaron G.L., BIOS Fund II QP, LP, BIOS Fund II NT, LP, BIOS Incysus Co-Invest I, LP, BIOS Fund III, LP, BIOS Fund III QP, LP, BIOS Fund III NT, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Purchase (P): 574,241 (derivative) · Purchase (P): 574,241 (derivative) · Purchase (P): 574,241 (derivative) | EDGAR |
| 2023-12-01 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Sale (S): 53,640 @ $3.44 · Sale (S): 91,708 @ $3.44 | EDGAR |
| 2023-11-13 | 4 | COGNITION THERAPEUTICS INC (CGTX) jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, BIOS Advisors GP, LLC, Bios Equity Partners, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Memory SPV I, LP, Bios Equity Partners II, LP, BIOS Fund II QP, LP | Grant/award (A): 500,095 @ $1.05 | EDGAR |
| 2023-06-23 | 4 | Azitra Inc (AZTR) jointly with Kreis Leslie W., Cavu Advisors, LLC, Cavu Management, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, Bios Equity Partners, LP, BIOS Fund II NT, LP, BIOS Fund II QP, LP, Bios Equity Partners II, LP | Sale (S): 77,953 · Purchase (P): 197,701 · Purchase (P): 69,880 @ $5 · Conversion (C): 137,186 · Sale (S): 509,141 · Purchase (P): 1,291,258 · +27 more | EDGAR |
| 2023-06-13 | 4 | COGNITION THERAPEUTICS INC (CGTX) jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, BIOS Advisors GP, LLC, Bios Equity Partners, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Memory SPV I, LP, Bios Equity Partners II, LP, BIOS Fund II QP, LP | Grant/award (A): 6,000 @ $0 · Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2022-12-13 | 4 | IN8BIO, INC. (INAB) jointly with Fletcher Aaron G.L., BIOS Fund II QP, LP, BIOS Fund II NT, LP, BIOS Incysus Co-Invest I, LP, BIOS Fund III, LP, BIOS Fund III QP, LP, BIOS Fund III NT, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Purchase (P): 9,214 @ $2.48 · Purchase (P): 57,052 @ $2.48 · Purchase (P): 8,735 @ $2.48 | EDGAR |
| 2022-11-29 | 4 | COGNITION THERAPEUTICS INC (CGTX) jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, BIOS Advisors GP, LLC, Bios Equity Partners, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Memory SPV I, LP, Bios Equity Partners II, LP, BIOS Fund II QP, LP | Purchase (P): 1,973 @ $2.65 · Purchase (P): 12,220 @ $2.65 · Purchase (P): 1,871 @ $2.65 | EDGAR |
| 2022-11-17 | 4 | COGNITION THERAPEUTICS INC (CGTX) jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, BIOS Advisors GP, LLC, Bios Equity Partners, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Memory SPV I, LP, Bios Equity Partners II, LP, BIOS Fund II QP, LP | Purchase (P): 8,722 @ $1.40 · Purchase (P): 54,009 @ $1.40 · Purchase (P): 8,269 @ $1.40 | EDGAR |
| 2022-11-16 | 4 | COGNITION THERAPEUTICS INC (CGTX) jointly with Fletcher Aaron G.L., BIOS Capital Management, LP, BIOS Advisors GP, LLC, Bios Equity Partners, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Memory SPV I, LP, Bios Equity Partners II, LP, BIOS Fund II QP, LP | Purchase (P): 184,270 @ $1.20 · Purchase (P): 1,141,030 @ $1.20 · Purchase (P): 174,700 @ $1.20 | EDGAR |
| 2022-11-09 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Sale (S): 58,711 @ $4.40 · Sale (S): 100,380 @ $4.40 · Sale (S): 17,748 @ $4.40 · Sale (S): 132,575 @ $4.40 · Sale (S): 40,586 @ $4.40 | EDGAR |
| 2022-09-29 | 4 | IN8BIO, INC. (INAB) jointly with Fletcher Aaron G.L., BIOS Fund II QP, LP, BIOS Fund II NT, LP, BIOS Incysus Co-Invest I, LP, BIOS Fund III, LP, BIOS Fund III QP, LP, BIOS Fund III NT, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Purchase (P): 3,070 @ $2.02 · Purchase (P): 19,017 @ $2.02 · Purchase (P): 2,913 @ $2.02 | EDGAR |
| 2022-09-07 | 4 | Lantern Pharma Inc. (LTRN) jointly with Fletcher Aaron G.L., BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, Bios Equity Partners, LP, Bios Equity Partners II, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC | Option exercise/expiry (X): 26,100 @ $1.03 · Sale (S): 5,170 @ $5.20 · Option exercise/expiry (X): 6,438 @ $1.03 · Sale (S): 1,275 @ $5.20 · Option exercise/expiry (X): 26,100 (derivative) @ $0 · Option exercise/expiry (X): 6,438 (derivative) @ $0 | EDGAR |
| 2022-08-30 | 4 | IN8BIO, INC. (INAB) jointly with Kreis Leslie W., BIOS Fund II NT, LP, BIOS Fund II QP, LP, BIOS Incysus Co-Invest I, LP, Bios Equity Partners II, LP, BIOS Equity Partners III, LP, Cavu Management, LP, Cavu Advisors, LLC | Purchase (P): 1,377 @ $2.01 · Purchase (P): 4,912 @ $2.02 · Purchase (P): 8,531 @ $2.01 · Purchase (P): 30,428 @ $2.02 · Purchase (P): 1,306 @ $2.01 · Purchase (P): 4,660 @ $2.02 | EDGAR |
| 2022-08-30 | 4 | IN8BIO, INC. (INAB) jointly with Fletcher Aaron G.L., BIOS Fund II NT, LP, BIOS Fund II QP, LP, BIOS Incysus Co-Invest I, LP, Bios Equity Partners II, LP, BIOS Equity Partners III, LP, Cavu Management, LP, Cavu Advisors, LLC | Purchase (P): 1,377 @ $2.01 · Purchase (P): 4,912 @ $2.02 · Purchase (P): 8,531 @ $2.01 · Purchase (P): 30,428 @ $2.02 · Purchase (P): 1,306 @ $2.01 · Purchase (P): 4,660 @ $2.02 | EDGAR |
| 2022-08-18 | 4 | IN8BIO, INC. (INAB) jointly with Kreis Leslie W., BIOS Fund II NT, LP, BIOS Fund II QP, LP, BIOS Incysus Co-Invest I, LP, Bios Equity Partners II, LP, BIOS Equity Partners III, LP, Cavu Management, LP, Cavu Advisors, LLC | Purchase (P): 6,142 @ $1.93 · Purchase (P): 38,035 @ $1.93 · Purchase (P): 5,823 @ $1.93 | EDGAR |
| 2022-08-17 | 4 | IN8BIO, INC. (INAB) jointly with Kreis Leslie W., BIOS Fund II NT, LP, BIOS Fund III QP, LP, BIOS Incysus Co-Invest I, LP, Bios Equity Partners II, LP, BIOS Equity Partners III, LP, Cavu Management, LP, Cavu Advisors, LLC | Purchase (P): 217,891 @ $1.90 · Purchase (P): 1,349,218 @ $1.90 · Purchase (P): 206,575 @ $1.90 | EDGAR |
| 2022-02-01 | 4/A | COGNITION THERAPEUTICS INC (CGTX) jointly with BIOS Memory SPV I, LP, BIOS Fund I, LP, BIOS Fund I QP, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, BIOS Memory SPV II, LP, BIOS Fund III, LP, BIOS Fund III QP, LP, BIOS Fund III NT, LP | Conversion (C): 1,424,014 | EDGAR |
| 2021-08-03 | 4 | IN8BIO, INC. (INAB) jointly with Kreis Leslie W., BIOS Fund II NT, LP, BIOS Fund II QP, LP, BIOS Incysus Co-Invest I, LP, Bios Equity Partners II, LP, BIOS Equity Partners III, LP, Cavu Management, LP, Cavu Advisors, LLC | Conversion (C): 574,432 · Conversion (C): 1,876,624 · Conversion (C): 251,211 · Conversion (C): 997,433 · Conversion (C): 340,712 · Conversion (C): 2,225,316 · +8 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-07-14 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1714576 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs